Last reviewed · How we verify

NCT03523676

Use of Red Cell Distribution Width for Prediction of New-onset Atrial Fibrillation in Critically Ill Sepsis Patients

Completed Last updated 14 May 2018
What this trial tests

trial testing Red Cell Distribution Width in Atrial Fibrillation New Onset in 70 participants. Completed in 10 March 2018.

Timeline
1 January 2017
Primary endpoint
1 January 2018
10 March 2018

Quick facts

Lead sponsorAin Shams University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment70
Start date1 January 2017
Primary completion1 January 2018
Estimated completion10 March 2018

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 18 to 65, any sex, with Atrial Fibrillation New Onset. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Red cell distribution width variations are increased in a variety of medical conditions such as congestive heart failure, acute myocardial infarction, pulmonary embolism, pneumonia, critical illness, and cardiac arrest , and is a predictor of mortality in the general population..

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation New Onset

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03523676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing